Myeloproliferative Neoplasms

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, explains the challenges of choosing optimal timing for allogeneic hematopoietic cell transplantation in myelofibrosis.

Adrián Mosquera Orgueira, MD, PhD, discusses whether machine learning could accurately predict OS and NRM outcomes after allo-HSCT in myelofibrosis.

The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.

Juan Carlos Hernández-Boluda, MD, PhD, discusses the rationale for using machine learning to predict OS outcomes after allo-HCT in myelofibrosis.

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

Raajit Rampal, MD, discusses typical clinical applications of the 4 FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Mikkael A. Sekeres, MD, discusses the implications of a study that found associations between smoking intensity and disease progression in MDS.

James K. McCloskey II, MD, discusses the advantages of the oral formulation of decitabine plus cedazuridine for patients with MDS and CMML.

Raajit Rampal, MD, PhD, discusses current JAK inhibitor treatment options for myelofibrosis and additional therapies being evaluated in clinical trials.

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

The European Commission has approved imetelstat for the treatment of patients with transfusion-dependent anemia in lower-risk myelodysplastic syndrome.

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

Tislelizumab regimen wins approval in ESCC, perioperative durvalumab plus chemotherapy boosts EFS in gastric/GEJ cancer, and more from OncLive this week.

The FDA has granted orphan drug designation to bexmarilimab for myelodysplastic syndromes.

Lisaftoclax plus azacitidine demonstrated clinical activity and was safe in higher-risk MDS.

Rusfertide improved responses vs placebo in phlebotomy-dependent polycythemia vera.

The siRNA divesiran was well-tolerated and reduced the number of phlebotomies that were required in patients with polycythemia vera.

Ruxolitinib plus standard GVHD prophylaxis reduced GVHD in patients with myelofibrosis undergoing transplant.

The combination of seclidemstat and azacitidine will resume study in a phase 1/2 trial in patients with MDS and CMML following a partial clinical hold.

AJ1-11095 is being evaluated in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia.

The JAK/ROCK inhibitor rovadicitinib may provide a safe and effective new treatment option for patients with myelofibrosis who progressed on ruxolitinib.

Fedratinib showed early improvements in platelet count in patients with myelofibrosis.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on treatment goals for anemia and transfusion independence in MDS.